CALL/VERTEX PHARMACEUTICALS/350/0.1/17.01.25 | Market Closed - BOERSE MUENCHEN 19:27:00 14/06/2024 BST | ||
| 13.74 EUR | +2.08% |
|
| Current month | +26.06% | ||
| 1 month | +51.99% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 13.74 | +2.08% |
| 13/06/24 | 13.46 | +0.75% |
| 12/06/24 | 13.36 | -3.05% |
| 11/06/24 | 13.78 | -0.93% |
| 10/06/24 | 13.91 | +0.07% |
Real-time BOERSE MUENCHEN
Last update June 14, 2024 at 07:27 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GP4M1R |
| ISIN | DE000GP4M1R3 |
| Date issued | 10/05/2023 |
| Strike | 350 $ |
| Maturity | 17/01/2025 (215 Days) |
| Parity | 10 : 1 |
| Emission price | 6.01 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.97 € |
|---|---|
| Lowest since issue | 4.82 € |
| Spread | 0.3 € |
| Spread % | 2.17% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant
